Chiglitazar is a drug for the treatment of type 2 diabetes. Chiglitazar was developed by Shenzhen Chipscreen Biosciences Ltd..
The API has now reached off-patent status, after being launched in 2021.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Chiglitazar and many others, contact info@pharmacheminvestor.com